This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Walter T. Hughes, MD; Sandor Feldman, MD; Harold W. Hermann, MD

Arch Dermatol. 1974;110(6):926-928.

Abstract
A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

Author Affiliations
From St. Jude Children's Research Hospital, Memphis (Drs. Hughes and Feldman), and the Medical Research Division, Mead Johnson Co., Evansville, Ind (Dr. Hermann).

Footnotes
Accepted for publication July 29, 1974.

Reprint requests to 332 N Lauderdale, Box 318, Memphis, TN 38101 (Dr. Hughes).

CiteULike    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter     What's this?